Health
ApoB: The Cholesterol Number Most Men Never Get Tested
Four numbers come back on a routine lipid panel and your doctor says they look fine. There is a fifth number that is usually missing, and a lot of researchers now think it is the one that matters most.
Most men handle a cholesterol test like a haircut. Someone hands over a sheet of numbers, the doctor says it looks fine, and it is forgotten by lunch. Total cholesterol, HDL, LDL, triglycerides. Four numbers, no context.
There is a fifth number that is usually not on that sheet. It is called apolipoprotein B, or apoB, and a growing pile of research says it is a sharper read on heart risk than the LDL number everybody quotes. Here is what it actually measures, when the standard panel can mislead you, and whether it is worth asking for. This is education, not medical advice.
What apoB actually counts
Cholesterol does not float loose in your blood. It rides inside particles. Every particle that can lodge in an artery wall, LDL, VLDL, remnants, and lipoprotein(a), carries exactly one molecule of apoB on its surface. One particle, one apoB.
So an apoB test is a headcount. It tells you how many of these particles are circulating. Your LDL cholesterol number tells you something different: how much cholesterol all those particles are hauling in total.
That difference sounds academic until you look at how artery damage actually starts. Cholesterol can only get into an artery wall while it is inside an apoB particle. How much ends up stuck there depends mostly on how many particles are pressing against the wall, not how loaded each one happens to be. And once inside, the smaller cholesterol-poor particles stick more readily than the big loaded ones, because they bind more tightly to the tissue underneath (Sniderman et al., 2019).
Think of traffic. LDL cholesterol tells you roughly how many passengers are on the road. ApoB tells you how many cars. If your cars are running half empty, you have more of them than the passenger count suggests. And it is the cars that jam the intersection.
Where the standard panel can mislead you
Most of the time LDL cholesterol and apoB agree, and either one does the job. The trouble is the times they do not, because those cases are not random. They cluster in a specific kind of guy.
When the two disagree, apoB is the more accurate read on risk. That gap shows up most in men with triglycerides in the mild to moderate range of roughly 175 to 880 mg/dL, men with type 2 diabetes, men carrying extra weight or metabolic syndrome, and men whose LDL is already under 70 (Langlois and Sniderman, 2020). In those men the particles tend to run small and cholesterol-poor. The LDL number comes back looking reassuring while the particle count is quietly high.
If you are a middle-aged man with a bit of a gut and triglycerides that creep up, that description probably fits you.
The largest test of this idea pulled from the UK Biobank and two big clinical trials. Researchers looked at 389,529 people not taking any cholesterol medication, followed for a median of about 11 years, plus 40,430 patients with established artery disease already on statins. Measured one at a time, apoB, non-HDL cholesterol, and triglycerides each tracked with heart attacks. But when all of them went into the model together, only apoB held up (Marston et al., 2022).
Put plainly: once you know the particle count, the cholesterol content stops adding much.
The part that is not just correlation
Plenty of health markers travel with risk without causing it. This one is different, and the evidence behind that claim is unusually deep.
A European Atherosclerosis Society panel pulled together more than 200 prospective cohort studies, genetic studies, and randomized trials covering over 2 million participants, more than 20 million person-years of follow-up, and over 150,000 cardiovascular events. The relationship was dose-dependent and consistent across every type of study they examined. People born with gene variants that keep their LDL particles low have correspondingly lower lifetime risk, which is about as close to a natural randomized trial as biology offers (Ference et al., 2017).
Two things from that review are worth sitting with. First, there was no sign of a floor. Lower kept tracking with lower across the whole range studied. Second, the effect grew with how long the exposure lasted. This is a cumulative bill, not a snapshot. A moderately high number at 35 is doing quiet work for decades before anything shows up on a stress test.
The number responds, and the size of the effect is knowable
The hard numbers here come from statin trials, because that is where the large randomized data lives.
A meta-analysis of 26 randomized trials covering 170,000 participants found that every 1.0 mmol/L drop in LDL cholesterol, roughly 39 mg/dL on a US lab report, cut major vascular events by about 22 percent per year, and death from any cause by about 10 percent. There was no threshold in the range studied, which suggests a 2 to 3 mmol/L reduction would cut risk by something like 40 to 50 percent (Cholesterol Treatment Trialists' Collaboration, 2010).
A follow-up analysis of 27 trials looked specifically at people at low risk, the group guidelines usually leave alone. Even in men whose five-year risk of a major vascular event was under 10 percent, each 1.0 mmol/L reduction meant about 11 fewer major vascular events per 1,000 people over five years (Mihaylova et al., 2012).
Worth being straight about what that does and does not mean. Eleven per thousand over five years is a real effect and a modest one at the individual level. Whether it is worth taking a daily medication is a genuine tradeoff, and it is a conversation for you and your prescriber, not something to settle from a blog post.
Should you ask for the test
ApoB is a cheap, standardized blood test. Labs worldwide measure it the same way, which is more than can be said for the calculated LDL number on most panels. It usually does not require fasting.
It is most worth asking about if you have triglycerides on the high side, type 2 diabetes or prediabetes, extra weight around the middle, a family history of early heart disease, or an LDL that came back fine while you still feel like your risk picture is murkier than the sheet suggests. If your panel is clean and you have none of that, apoB will most likely just confirm what LDL already told you.
One thing not to do is chase a target number you picked up online. Appropriate apoB goals depend on your overall risk, and that is exactly the sort of judgment your doctor is trained to make.
What actually moves it
Nothing here will surprise you, and that is the point. The particle count responds to the same levers as the rest of your metabolic health: losing excess body fat, cutting back on saturated fat, eating more soluble fiber, training regularly, and being honest about alcohol. Men with high triglycerides and a big waist tend to see the most movement, because they had the most room.
Lifestyle changes generally shift these numbers less than medication does. That is not an argument against doing them, since every one of those habits pays off in ways that have nothing to do with a lab value. It is an argument against expecting a clean diet alone to fix a number that is badly out of range.
When to stop reading and make an appointment
Talk to a doctor if you have a family history of heart attack or stroke before age 55 in men or 65 in women, if your LDL has come back high more than once, if you have diabetes or metabolic syndrome, or if you have never had a lipid panel and you are over 35. If you already take a cholesterol medication, talk to your prescriber before changing anything based on a number you read about.
The verdict
ApoB counts the particles that do the damage. LDL cholesterol estimates what those particles are carrying. Most of the time they say the same thing, and when they disagree, the particle count is the one that has been right in the large studies.
You do not need to become a lipid nerd. Ask for apoB the next time blood gets drawn, especially if your triglycerides run high or your waist has been creeping. Then take the number to someone who can put it in context with the rest of your risk. That is the verdict.
References
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019. https://pubmed.ncbi.nlm.nih.gov/31642874/
- Langlois MR, Sniderman AD. Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease? Curr Cardiol Rep. 2020. https://pubmed.ncbi.nlm.nih.gov/32562186/
- Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiol. 2022. https://pubmed.ncbi.nlm.nih.gov/34773460/
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. Eur Heart J. 2017. https://pubmed.ncbi.nlm.nih.gov/28444290/
- Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010. https://pubmed.ncbi.nlm.nih.gov/21067804/
- Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012. https://pubmed.ncbi.nlm.nih.gov/22607822/
Common questions
What is apoB and how is it different from LDL cholesterol?
ApoB, or apolipoprotein B, is a protein that sits on the surface of every artery-clogging lipoprotein particle in your blood, including LDL, VLDL, remnants, and lipoprotein(a). Each particle carries exactly one molecule of it, so an apoB test is essentially a count of how many of those particles you have. LDL cholesterol measures something different: the total amount of cholesterol those particles are carrying. Since cholesterol can only enter an artery wall while it is inside an apoB particle, the particle count is the closer match to what actually drives artery damage (Sniderman, 2019).
Is apoB really better than LDL cholesterol at predicting heart risk?
In the largest analysis to date, yes. Researchers studied 389,529 people not on cholesterol medication, followed for a median of about 11 years, plus 40,430 patients with existing artery disease on statins. On their own, apoB, non-HDL cholesterol, and triglycerides each tracked with heart attack risk. When all of them were assessed together, only apoB remained associated (Marston, 2022). That said, LDL and apoB agree most of the time, so for many men the standard panel tells the same story.
Who should ask their doctor for an apoB test?
It adds the most for men whose LDL and apoB are likely to disagree. That means high triglycerides in the mild to moderate range, type 2 diabetes, extra weight or metabolic syndrome, or an LDL already under 70 (Langlois and Sniderman, 2020). A family history of early heart disease is another good reason to ask. If your panel is clean and none of that applies, apoB will probably just confirm what your LDL already showed.
What is a good apoB number?
There is no single number that fits everyone. Appropriate targets depend on your overall cardiovascular risk, which factors in age, blood pressure, smoking, diabetes, and family history. Chasing a target you found online is a bad idea. Get the test, then have your doctor interpret it alongside the rest of your risk picture.
Can diet and exercise lower apoB, or does it take medication?
Both move it. Losing excess body fat, cutting saturated fat, eating more soluble fiber, training regularly, and drinking less all push the number down, and men with high triglycerides and a large waist tend to see the biggest shifts. Lifestyle changes generally move it less than medication does, though. The large randomized numbers, such as roughly a 22 percent drop in major vascular events per 1.0 mmol/L of LDL lowering, come from statin trials (Cholesterol Treatment Trialists' Collaboration, 2010). Whether medication makes sense for you is a conversation with your prescriber.
